Article Information
History
- August 10, 2021.
Article Versions
- You are currently viewing Version 1 of this article (August 10, 2021 - 08:25).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Alexander Wilhelm1,
- Tuna Toptan1,
- Christiane Pallas1,
- Timo Wolf2,3,
- Udo Goetsch4,
- Rene Gottschalk4,
- Maria JGT Vehreschild2,3,5,
- Sandra Ciesek1,5,6,# and
- Marek Widera1,*,#
- 1Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
- 2Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
- 3University Center for Infectious Diseases (UCI), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
- 4Health Protection Authority of the City of Frankfurt am Main, Frankfurt am Main, Germany
- 5German Center for Infection Research, DZIF, Braunschweig, Germany
- 6Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch Translational Medicine and Pharmacology, Frankfurt am Main, Germany
- ↵*Correspondence: Dr. Marek Widera, Institute for Medical. Virology, University Hospital Frankfurt, Paul-Ehrlich-Str.40, 60596 Frankfurt am Main, Tel: +49 69 6301 – 86102, Fax: +49 69 6301 – 6477, email: marek.widera{at}kgu.de
↵# contributed equally
Posted August 10, 2021.
Antibody-mediated neutralization of authentic SARS-CoV-2 B.1.617 variants harboring L452R and T478K/E484Q
